Jpmorgan Chase & CO C4 Therapeutics, Inc. Transaction History

Jpmorgan Chase & CO

  • $1.27 Trillion
  • Q1 2025

A detailed history of Jpmorgan Chase & CO transactions in C4 Therapeutics, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 34,419 shares of CCCC stock, worth $72,624. This represents 0.0% of its overall portfolio holdings.

Number of Shares
34,419
Previous 33,409 3.02%
Holding current value
$72,624
Previous $120,000 54.17%
% of portfolio
0.0%
Previous 0.0%

Shares

20 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2025

May 12, 2025
BUY
$1.6 - $4.09 $1,616 - $4,130
1,010 Added 3.02%
34,419 $55,000
Q4 2024

Feb 12, 2025
BUY
$3.6 - $7.0 $27,468 - $53,410
7,630 Added 29.6%
33,409 $120,000
Q3 2024

Dec 26, 2024
BUY
$4.43 - $7.38 $3,481 - $5,800
786 Added 3.14%
25,779 $146,000
Q3 2024

Nov 08, 2024
BUY
$4.43 - $7.38 $3,481 - $5,800
786 Added 3.14%
25,779 $146,000
Q2 2024

Dec 26, 2024
SELL
$4.05 - $8.1 $3,183 - $6,366
-786 Reduced 3.05%
24,993 $115,000
Q2 2024

Aug 12, 2024
BUY
$4.05 - $8.1 $101,197 - $202,394
24,987 Added 416450.0%
24,993 $115,000
Q1 2024

Dec 26, 2024
SELL
$5.3 - $11.0 $136,596 - $283,503
-25,773 Reduced 99.98%
6 $0
Q1 2024

May 10, 2024
SELL
$5.3 - $11.0 $36,501 - $75,757
-6,887 Reduced 99.91%
6 $0
Q4 2023

Dec 26, 2024
SELL
$1.18 - $6.03 $22,285 - $113,882
-18,886 Reduced 73.26%
6,893 $38,000
Q4 2023

Feb 12, 2024
SELL
$1.18 - $6.03 $2,645 - $13,519
-2,242 Reduced 24.54%
6,893 $38,000
Q3 2023

Nov 14, 2023
BUY
$1.81 - $3.89 $13,813 - $29,688
7,632 Added 507.78%
9,135 $16,000
Q2 2023

Aug 11, 2023
SELL
$2.75 - $3.77 $88,990 - $121,997
-32,360 Reduced 95.56%
1,503 $4,000
Q1 2023

May 18, 2023
BUY
$3.1 - $9.02 $99,891 - $290,651
32,223 Added 1964.82%
33,863 $106,000
Q1 2023

May 11, 2023
SELL
$3.1 - $9.02 $306,410 - $891,554
-98,842 Reduced 98.37%
1,640 $5,000
Q4 2022

Feb 13, 2023
BUY
$5.42 - $10.24 $401,714 - $758,958
74,117 Added 281.12%
100,482 $592,000
Q3 2022

Nov 14, 2022
BUY
$8.03 - $12.77 $12,711 - $20,214
1,583 Added 6.39%
26,365 $231,000
Q2 2022

Aug 11, 2022
SELL
$5.06 - $26.46 $225,868 - $1.18 Million
-44,638 Reduced 64.3%
24,782 $187,000
Q1 2022

May 11, 2022
BUY
$19.99 - $33.23 $813,553 - $1.35 Million
40,698 Added 141.7%
69,420 $1.68 Million
Q4 2021

Feb 10, 2022
SELL
$29.39 - $46.86 $767,284 - $1.22 Million
-26,107 Reduced 47.62%
28,722 $925,000
Q3 2021

Nov 12, 2021
BUY
$35.91 - $50.5 $1.97 Million - $2.77 Million
54,829 New
54,829 $2.45 Million

Others Institutions Holding CCCC

# of Institutions
105
Shares Held
57.2M
Call Options Held
15.2K
Put Options Held
0
View Full List

About C4 Therapeutics, Inc.

CCCC Quotes by TradingView
  • Ticker CCCC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 48,913,800
  • Market Cap $103M
  • Description
  • C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting ...
More about CCCC
Track This Portfolio

Track Jpmorgan Chase & CO Portfolio

Follow Jpmorgan Chase & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email